Carcinoma

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Patient, PST, Prostate cancer, Carcinoma, Bladder cancer, ASCO, Team Impulse, Society, TSC1, Urethra, GU, TSC2, Progress, Kidney cancer, Cancer

LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.

Key Points: 
  • LOS ANGELES, Jan. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place January 25-27, 2024, in San Francisco, CA.
  • Abstract and poster presentation details are below:
    Date/Time: January 26, 2024 – 11:30 – 1:00 pm; 5:45 – 6:45 pm PST
    In a large real-world database of patients with advanced cancer, 1,828 (4.0%) of the 46,068 patients with GU cancers had at least one inactivating alteration in TSC1 or TSC2
    TSC1 and/or TSC2 inactivating alterations were present in 9.2% of patients with bladder cancer, 6.4% of patients with kidney cancer, and 0.6% of patients with prostate cancer
    Aadi is also presenting an encore Trials-in-Progress (TiP) poster from the ongoing PRECISION 1 study.
  • Session Title: Trials in Progress Poster Session C: Renal Cell Cancer: Adrenal, Penile, Urethral and Testicular Cancers
    Date/Time: January 27, 2024 – 7:00 – 8:00 am; 11:30 am – 1:00 pm PST

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

Retrieved on: 
Friday, January 26, 2024
Neoplasm, Carcinoma, Therapy, Flare, ADC, UC, Biotechnology, Knowledge, ASCO, PPARG, Cancer, Factorization of polynomials, PD, Human, Safety, Biomarker, TME, Pharmacokinetics

CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, today announced a poster presentation outlining the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG, at the 2024 ASCO Genitourinary Cancers Symposium taking place from January 25-27, 2024 in San Francisco, CA.

Key Points: 
  • "FlareTx has built a robust body of preclinical evidence that supports investigation of FX-909 in clinical trials in patients," said Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of Flare Therapeutics. "
  • Results shown to date reveal that FX-909 eradicates tumors in urothelial cancer (UC) animal models at low oral doses.
  • Exploratory objectives include the evaluation of patient selection biomarkers from tissue and blood samples and association with clinical outcomes.
  • In the US, approximately 10 sites are planned for Phase 1A and 12-15 sites for Phase 1B.

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio

Retrieved on: 
Friday, January 26, 2024
Bristol Myers Squibb, Cytotoxicity, Research, Incidence, Melanoma, ROW, Biotechnology, AstraZeneca, Ipilimumab, HDAC, Carcinoma, Bone marrow suppression, Growth, BioNTech, Bio-Techne, NSCLC, Combination therapy, Investment, Disease, BMS, USD, FDA, Diarrhea, HBM, Hair loss, Merck, CTLA4, Immune system, Pharmaceutical industry

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from  2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.

Key Points: 
  • High target affinity and specificity of CTLA4 inhibitors are notably driving the growth.
  • Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
  • The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
  • The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Retrieved on: 
Tuesday, January 16, 2024
DISCO, Stanford University, Patient, Sofinnova, Therapy, Research, Colorectal cancer, Umoja, University, Map, COYA, Pfizer, Drug discovery, EVP, Roche, Spacecraft, SCLC, ETH, BMS, Protein, CDO, Genome, Bayer, Doctor of Philosophy, Proteomics, Merck Group, Carcinoma

Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

Key Points: 
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
  • COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
  • The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
  • Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Retrieved on: 
Tuesday, January 16, 2024
DISCO, Stanford University, Patient, Sofinnova, Therapy, Research, Colorectal cancer, Umoja, University, Map, COYA, Pfizer, Drug discovery, EVP, Roche, Spacecraft, SCLC, ETH, BMS, Protein, CDO, Genome, Bayer, Doctor of Philosophy, Proteomics, Merck Group, Carcinoma

Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.

Key Points: 
  • Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.
  • COLOGNE, Germany and ZURICH, Jan. 16, 2024 /PRNewswire/ -- DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking the surfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth today.
  • The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing of EUR 20 million and is backed by a world leading investor syndicate, including Sofinnova Partners, which led the round, Panakes Partners, M Ventures and AbbVie Ventures.
  • Roman Thomas, Founder and Chief Executive Officer, at DISCO Pharmaceuticals, said: "Today, we are launching DISCO Pharmaceuticals and its breakthrough technology after a decade of research by our exceptional team.

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Retrieved on: 
Monday, January 8, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, MSD, Harpoon, Neoplasm, Construct, Multimedia, Physician, B-cell maturation antigen, Acquisition, Centerview Partners, Epithelial cell adhesion molecule, BCMA, Pharmacokinetics, Covington & Burling, Carcinoma, Merck & Co., SCLC, Patient, Safety, MRK, Creativity, DLL3, Glomus tumor, Pharmaceutical industry

“This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon.

Key Points: 
  • “This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon.
  • “At Harpoon, we have always been committed to advancing our cancer immunotherapy candidates to improve the lives of patients.
  • Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Harpoon Therapeutics, Inc. for a price per share of $23.00 in cash.
  • Centerview Partners LLC acted as financial advisor to Harpoon and Goodwin Procter LLP acted as its legal advisor.

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Retrieved on: 
Friday, January 5, 2024
Codevelopment, Protein, Partnership, Kidney, Molecular Partners, Novartis, DARPin, RDT, Patient, Carcinoma, Therapy, DLL3, Radiation, Pharmaceutical industry

This agreement represents the first co-development deal for Molecular Partners and Orano Med.

Key Points: 
  • This agreement represents the first co-development deal for Molecular Partners and Orano Med.
  • Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.
  • Under the terms of the co-development agreement, Molecular Partner’s previously disclosed RDT target DLL3 (delta-like ligand 3) will be included in the partnership with Orano Med.
  • DLL3 will be exclusively developed by Molecular Partners and Orano Med as a RDT target.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024
Patient, CRC, Stage 2, IND, FDA, BTC, Research and development, PD-1, DLL4, CD137, PET, Melanoma, MD, Doctor of Philosophy, Therapy, Mesothelioma, Paclitaxel, Carcinoma, SCLC, Safety, Development, NSCLC, PD-L1, Pharmaceutical industry

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Friday, January 5, 2024
Part Two, Skin cancer, Pain, Carcinoma, Patient, Scar, Dermatology, Skin, Therapy, Infection, Part

WEST CHESTER, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of VP-315, a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma.

Key Points: 
  • “We are pleased to announce that Part 2 of our Phase 2 clinical trial of VP-315 for the treatment of basal cell carcinoma has been fully enrolled and the last patient has been dosed,” said Ted White, Verrica’s President and Chief Executive Officer.
  • “Basal cell carcinoma is the most common form of skin cancer in the U.S. each year and patients are in need of alternative solutions to surgery which can cause pain, infection and scarring.
  • Verrica’s VP-315 program is designed to provide for the targeted delivery of an oncolytic peptide engineered to stimulate the patient’s immune system and destroy cancer cells.
  • Our study remains on track, and we look forward to sharing the data from our Phase 2 clinical trial later this year.”

Genprex Provides Business Update and Outlook for 2024

Retrieved on: 
Friday, January 5, 2024
NPRL2, Atezolizumab, FDA, Lung cancer, Cancer, MAF (gene), University of Pittsburgh, Treatment, SCLC, Autoimmunity, Pembrolizumab, Conference, Type 1, IND, Pancreas, Disease, Orphan, ATTD, University, Carcinoma, Merck, NSCLC, Patient, AACR, Food, Neoplasm, Immune system, AstraZeneca, Type 2, Apoptosis, Tumor suppressor gene, AAV, Toxicity, MAFB (gene), Genentech, NHP, Research, Insulin, C-peptide, Clinical trial, Investigational New Drug, PDX1, Pharmaceutical industry

AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.

Key Points: 
  • Our accomplishments in 2023, which also include process improvements in our manufacturing operations and securing new supplies of REQORSA, sets the foundation for a strong 2024."
  • Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles.
  • In May, Genprex completed the Phase 1 portion of the Acclaim-1 clinical trial and reported encouraging results.
  • In October 2023, Genprex entered into a one-year extension to the August 2022 sponsored research agreement with the University of Pittsburgh.